Vanguard Diversified High Growth Index ETF

VDHG

VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.

Global X S&P Biotech ETF

CURE

CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The ETF currently has 31.41m in AUM and 122 holdings. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.

Vanguard Australian Property Securities Index ETF

VAP

VAP.AX was created on 2010-10-11 by Vanguard. The fund's investment portfolio concentrates primarily on real estate equity. Vanguard Australian Property Securities Index Fund seeks to track the return of the S&P/ASX 300 A-REIT Index before taking into account fees, expenses and tax.

Betashares Nasdaq 100 ETF

NDQ

NDQ.AX was created on 2015-05-26 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The fund aims to track the performance of the NASDAQ-100 Index (before fees and expenses). The NASDAQ-100 comprises 100 of the largest non-financial companies listed on the NASDAQ market, and includes many companies that are at the forefront of the new economy.

Lumos Diagnostics Holdings Limited

LDX

Lumos Diagnostics Holdings Ltd. engages in the development and manufacture of point-of-care diagnostics solutions to help healthcare professionals more accurately diagnose and manage medical conditions. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2021-07-05. The firm offers customized assay development and manufacturing services for POC tests and digital reader platforms. The company also directly develops, manufactures, and commercializes Lumos-branded POC tests that target infectious and inflammatory diseases. Its Products offering is based on developing and commercializing its own suite of POC diagnostic products which are primarily focused on the diagnosis and management of infectious diseases. These include FebriDx, a POC test for detecting and differentiating viral and bacterial respiratory infections, and ViraDx, a rapid point-of-care diagnostic product that simultaneously tests for acute respiratory infections caused by the COVID-19, influenza A, and influenza B viruses. The company manages the full development program for POC assays.